Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
BMC Cancer|March 16, 2019
A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA)Nadja M Meindl-Beinker, Johannes Betge, Tobias Gutting, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|December 23, 2021
Expression of the EGFR-RAS Inhibitory Proteins DOK1 and MTMR7 and its Significance in Colorectal Adenoma and Adenoma RecurrenceTobias Gutting, Andreas Merkel, David J Fink, et al.
BMC Cancer|July 20, 2018
A multicenter phase 4 geriatric assessment directed trial to evaluate gemcitabine +/- nab-paclitaxel in elderly pancreatic cancer patients (GrantPax)Johannes Betge, Jing Chi-Kern, Nadine Schulte, et al.
International Journal of Cancer|September 20, 2018
Single-cell genetic analysis of clonal dynamics in colorectal adenomas indicates CDX2 gain as a predictor of recurrenceDavid Fiedler, Kerstin Heselmeyer-Haddad, Daniela Hirsch, et al.
Molecular Oncology|June 30, 2019
Detection of mutational patterns in cell-free DNA of colorectal cancer by custom amplicon sequencingSimon Herrmann, Tianzuo Zhan, Johannes Betge, et al.
Experimental Hematology|March 30, 2006
Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myelomaMichael Hundemer, Stefanie Schmidt, Maud Condomines, et al.
Genes, Chromosomes & Cancer|July 24, 2019
Genome-wide DNA methylation analysis of colorectal adenomas with and without recurrence reveals an association between cytosine-phosphate-guanine methylation and histological subtypesDavid Fiedler, Daniela Hirsch, Nady El Hajj, et al.
International Journal of Radiation Oncology, Biology, Physics|September 6, 2017
Panitumumab in Combination With Preoperative Radiation Therapy in Patients With Locally Advanced RAS Wild-type Rectal Cancer: Results of the Multicenter Explorative Single-Arm Phase 2 Study NEORITKirsten Merx, Uwe M Martens, Melanie Kripp, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 2, 2009
Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24Olaf Christensen, Alaviana Lupu, Stefanie Schmidt, et al.
European Journal of Haematology|March 28, 2008
Identification of HLA-A2 restricted T-cell epitopes within the conserved region of the immunoglobulin G heavy-chain in patients with multiple myelomaSebastian Belle, Fang Han, Maud Condomines, et al.
Pageof 6